Form 4 for ABT Abbott Laboratories
Accepted 2023-08-10 00:00:00 ET · period of report 2023-08-08 · accession 0001415889-23-012074 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-08-10 | 2023-08-08 | ABT | Wainer Andrea F | EVP | S - Sale+OE | $105.03 | -10.4K | 65.0K | -14% | -$1.09M |
| D | 2023-08-10 | 2023-08-08 | ABT | Wainer Andrea F | EVP | M - OptEx | $38.40 | +5,000 | 75.4K | +7% | +$192.0K |
| D | 2023-08-10 | 2023-08-08 | ABT | Wainer Andrea F | EVP | M - OptEx | $0.00 | -5,000 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common shares without par value | 2023-08-08 | S | D | 5,112 | $105.00 | 65,315 | D | — | — | |
| 2 | Common | Common shares without par value | 2023-08-08 | S | D | 4,741 | $105.00 | 70,686 | D | — | — | |
| 3 | Common | Common shares without par value | 2023-08-08 | S | D | 272 | $105.43 | 65,043 | D | — | — | |
| 4 | Common | Common shares without par value | 2023-08-08 | M | A | 5,000 | $38.40 | 75,427 | D | — | — | |
| 5 | Common | Common shares without par value | 2023-08-08 | S | D | 15 | $107.42 | 70,427 | D | — | — | |
| 6 | Common | Common shares without par value | 2023-08-08 | S | D | 244 | $105.43 | 70,442 | D | — | — | |
| 7 | Common | Common shares without par value | 2023-08-08 | S | D | 16 | $107.42 | 65,027 | D | — | — | |
| 8 | Derivative | Option (right to buy) | 2023-08-08 | M | D | 5,000 | $0.00 | 0 | D | $38.40 · 2019-02-19 to 2026-02-18 | 5,000 Common Shares | (F1) Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. |